Allergic diseases of the skin and drug allergies – 2004: Clinical and immunologic characteristics of allergen-specific immunotherapy in children with atopic dermatitis

Results The efficacy after 12M of APAI was 78.7–84.8% depending on disease severity. The “excellent” result after APAI course was achieved in 21.2% Ch with AD, “good” in 57.6% Ch, “satisfactory” in 9.1% Ch, and there was no therapeutic effect in 12.1% Ch. There was reduction in the number, duration and severity of AD exacerbations observed in 2/3 Ch, which allowed the subsequent reduction of BT. As early as at 6 M there was a 1.5 times decrease of hospitalization number (p<0.05) as compared to the pre-treatment year. After the 1st M of APAI in Ch with AD there was no significant decrease of SC of IL-4, IL-13 and no increase of saliva IFNg level either (p<0.05). There was no normalization of SC IL-4 and IL-13 during first 6 months in Ch with severe AD as well, though their levels decreased at an average of more than 1.5 times. 12 M of APAI provided duplication of local SC of IFNg. This saliva IFNg increase in Ch with AD on the background of APAI was accompanied by decrease of specific IgE againstHDMA (r= –0.73). The pre-APAI immune disorder formula was IL-43+IL-132+IFNg3-IgE3+. After termination of treatment course withHDMA it has changed for IL-42+IL-132+IFNg1-IgE2+.